Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation
Autor(a) principal: | |
---|---|
Data de Publicação: | 2024 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Revista do Instituto de Medicina Tropical de São Paulo |
Texto Completo: | https://www.revistas.usp.br/rimtsp/article/view/221851 |
Resumo: | Hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation. |
id |
IMT-1_57a05539ddbf7107026f335c1a60ebb8 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/221851 |
network_acronym_str |
IMT-1 |
network_name_str |
Revista do Instituto de Medicina Tropical de São Paulo |
repository_id_str |
|
spelling |
Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantationHepatitis CHematopoietic stem cell transplantationPrevalenceClinical outcomeHepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation.Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo2024-02-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/rimtsp/article/view/22185110.1590/S1678-9946202466011Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e11Revista do Instituto de Medicina Tropical de São Paulo; v. 66 (2024); e11Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e111678-99460036-4665reponame:Revista do Instituto de Medicina Tropical de São Pauloinstname:Instituto de Medicina Tropical (IMT)instacron:IMTenghttps://www.revistas.usp.br/rimtsp/article/view/221851/202731Copyright (c) 2024 Ana Claudia Marques Barbosa Diaz, Steven Sol Witkin, Cesar de Almeida Neto, Vanderson Rocha, Silvia Figueiredo Costa, Jessica Fernandes Ramos, Maria Cassia Mendes-Correahttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessDiaz, Ana Claudia Marques Barbosa Witkin, Steven Sol Almeida Neto, Cesar de Rocha, VandersonCosta, Silvia Figueiredo Ramos, Jessica Fernandes Mendes-Correa, Maria Cassia 2024-05-06T14:04:52Zoai:revistas.usp.br:article/221851Revistahttp://www.revistas.usp.br/rimtsp/indexPUBhttps://www.revistas.usp.br/rimtsp/oai||revimtsp@usp.br1678-99460036-4665opendoar:2024-05-06T14:04:52Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT)false |
dc.title.none.fl_str_mv |
Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation |
title |
Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation |
spellingShingle |
Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation Diaz, Ana Claudia Marques Barbosa Hepatitis C Hematopoietic stem cell transplantation Prevalence Clinical outcome |
title_short |
Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation |
title_full |
Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation |
title_fullStr |
Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation |
title_full_unstemmed |
Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation |
title_sort |
Prevalence and clinical consequences of Hepatitis C virus infection in patients undergoing hematopoietic stem cell transplantation |
author |
Diaz, Ana Claudia Marques Barbosa |
author_facet |
Diaz, Ana Claudia Marques Barbosa Witkin, Steven Sol Almeida Neto, Cesar de Rocha, Vanderson Costa, Silvia Figueiredo Ramos, Jessica Fernandes Mendes-Correa, Maria Cassia |
author_role |
author |
author2 |
Witkin, Steven Sol Almeida Neto, Cesar de Rocha, Vanderson Costa, Silvia Figueiredo Ramos, Jessica Fernandes Mendes-Correa, Maria Cassia |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Diaz, Ana Claudia Marques Barbosa Witkin, Steven Sol Almeida Neto, Cesar de Rocha, Vanderson Costa, Silvia Figueiredo Ramos, Jessica Fernandes Mendes-Correa, Maria Cassia |
dc.subject.por.fl_str_mv |
Hepatitis C Hematopoietic stem cell transplantation Prevalence Clinical outcome |
topic |
Hepatitis C Hematopoietic stem cell transplantation Prevalence Clinical outcome |
description |
Hepatitis C virus (HCV) infection is a significant cause of morbidity and mortality among hematopoietic stem cell transplant (HCT) recipients. In Brazil, its occurrence in HCT recipients remains undetermined. We now report on HCV prevalence in HCT recipients and its clinical consequences. The medical records of all HCT recipients seen at Hospital das Clinicas, Sao Paulo University Medical School, from January 2010 to January 2020 were reviewed to determine HCV serostatus. A retrospective analysis of medical charts was undertaken on all seropositive cases to determine HCV genotype, presence of liver fibrosis, co-infections with other viruses, previous treatments, and clinical evolution of liver pathology after HCT. Of the 1,293 HCT recipients included in the study, seven (0.54%) were HCV antibody-positive and five (0.39%) were also viremic for HCV-RNA. Four of these individuals had moderate to severe liver fibrosis (METAVIR F2/F3) and one was cirrhotic. Two of the viremic patients developed acute liver dysfunction following transplantation. All patients had their acute episode of liver dysfunction resolved with no further complications. Four of the viremic patients were treated for HCV infection with direct acting agents (DAA). Information regarding HCV treatment was lacking for one of the viremic HCV patients due to loss of follow up. Sustained anti-virologic responses were observed in three cases after the use of DAA. The detection of HCV in hematological adults undergoing HCT and its successful treatment with DAA highlight the necessity of testing for HCV both prior to and following transplantation. |
publishDate |
2024 |
dc.date.none.fl_str_mv |
2024-02-07 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/rimtsp/article/view/221851 10.1590/S1678-9946202466011 |
url |
https://www.revistas.usp.br/rimtsp/article/view/221851 |
identifier_str_mv |
10.1590/S1678-9946202466011 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/rimtsp/article/view/221851/202731 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo |
publisher.none.fl_str_mv |
Universidade de São Paulo. Instituto de Medicina Tropical de São Paulo |
dc.source.none.fl_str_mv |
Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e11 Revista do Instituto de Medicina Tropical de São Paulo; v. 66 (2024); e11 Revista do Instituto de Medicina Tropical de São Paulo; Vol. 66 (2024); e11 1678-9946 0036-4665 reponame:Revista do Instituto de Medicina Tropical de São Paulo instname:Instituto de Medicina Tropical (IMT) instacron:IMT |
instname_str |
Instituto de Medicina Tropical (IMT) |
instacron_str |
IMT |
institution |
IMT |
reponame_str |
Revista do Instituto de Medicina Tropical de São Paulo |
collection |
Revista do Instituto de Medicina Tropical de São Paulo |
repository.name.fl_str_mv |
Revista do Instituto de Medicina Tropical de São Paulo - Instituto de Medicina Tropical (IMT) |
repository.mail.fl_str_mv |
||revimtsp@usp.br |
_version_ |
1798951636651999232 |